论文部分内容阅读
运用异型双功能交联剂2—亚氨基四氢噻吩将抗人 T 淋巴细胞单克隆抗体 H65(CD5)与单链核糖体失活蛋白苦瓜毒素2及玉竹毒素2偶联后形成的免疫毒素分别称之为 H65—MOR2及 H65—PGN2.体外实验表明上述两种免疫毒素对靶细胞 Molt—4及正常人周血 T 淋巴细胞具有明显的特异性细胞毒作用,而对骨髓中的造血祖细胞没有影响。Balb/c 裸鼠皮下注射 Molt—4细胞,待长出实体瘤以后,腹腔注射免疫毒素 H65—MOR2或 H65—PGN2U10μ(?)/只/48小时可以特异性地抑制肿瘤的生长.实验结果表明这类免疫毒素可以用于体内治疗肿瘤转移灶、某些自身免疫性疾病以及在异体骨髓移植中清除引起移植物抗宿主病(GVHD)的 T 细胞.
The immunotoxin formed by coupling the anti-human T lymphocyte monoclonal antibody H65 (CD5) and the single-chain ribosomal inactivation protein Momordicin-2 and Diphtheria toxin 2 with the heterobifunctional crosslinking agent 2-iminothiolane Respectively called H65-MOR2 and H65-PGN2 in vitro experiments show that the two kinds of immunotoxins on target cells Molt-4 and normal human peripheral blood T lymphocytes with significant specific cytotoxicity, and bone marrow hematopoietic progenitor Cells have no effect. Molt-4 cells were injected subcutaneously in Balb / c nude mice, and tumor growth was inhibited specifically by intraperitoneal injection of immunotoxin H65-MOR2 or H65-PGN2U10μ (?) / Only for 48 hours after solid tumor growth. Such immunotoxins can be used to treat tumor metastases in vivo, certain autoimmune diseases and the clearance of T cells that cause graft-versus-host disease (GVHD) in allogeneic bone marrow transplantation.